These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors. Nandakumar V; Mills JR Clin Chem; 2019 Feb; 65(2):357. PubMed ID: 32100826 [No Abstract] [Full Text] [Related]
3. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Tray N; Taff J; Singh B; Suh J; Ngo N; Kwa M; Troxel AB; Chae YK; Kurzrock R; Patel SP; Sharon E; Denkert C; Ross JS; Adams S Breast; 2019 Apr; 44():29-32. PubMed ID: 30609392 [TBL] [Abstract][Full Text] [Related]
4. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052 [TBL] [Abstract][Full Text] [Related]
5. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217 [TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling: Building a Continuum From Knowledge to Care. Chen HX; Abrams JS JAMA Oncol; 2015 Jul; 1(4):474-5. PubMed ID: 26181257 [No Abstract] [Full Text] [Related]
7. Development and Validation of Molecular Assays for Limited Tissue Samples. Sussman R; Rosenbaum JN Acta Cytol; 2020; 64(1-2):147-154. PubMed ID: 30995656 [TBL] [Abstract][Full Text] [Related]
8. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837 [TBL] [Abstract][Full Text] [Related]
9. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms. Riedlinger G; Hadigol M; Khiabanian H; Ganesan S JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212 [TBL] [Abstract][Full Text] [Related]
10. Multigene Panel Testing in Oncology Practice: How Should We Respond? Kurian AW; Ford JM JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167 [No Abstract] [Full Text] [Related]
16. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. Yarchoan M; Hopkins A; Jaffee EM N Engl J Med; 2017 Dec; 377(25):2500-2501. PubMed ID: 29262275 [No Abstract] [Full Text] [Related]
17. A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day. Uguen A; Troncone G J Clin Pathol; 2018 Sep; 71(9):757-762. PubMed ID: 29903742 [No Abstract] [Full Text] [Related]
18. New ESMO scale ranks mutations as cancer medicine targets. Fricker J Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495 [No Abstract] [Full Text] [Related]
19. Blood-based tumour mutational burden analysis in NSCLC. Das M Lancet Oncol; 2018 Sep; 19(9):e446. PubMed ID: 30122616 [No Abstract] [Full Text] [Related]